香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 民銀資本控股有限公司 CMBC CAPITAL HOLDINGS LIMITED （ 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ） （股份代號：1141） 有關購買可換股證券 的須予披露的交易 購買事項 於二零二五年九月二十五日，本公司全資附屬公司民銀投資（香港）已於場外交易市場 購買本金總額為20,000,000美元（相當於約155,842,000港元）的可換股證券，總代價為約 21,356,951.39美元（相當於約166,415,500.93港元）。 上市規則的涵義 由於購買事項的最高相關適用百分比率（定義見上市規則）超出5%但低於25%，購買事 項構成本公司的須予披露的交易，須遵守上市規則第14章的匯報及公告規定，惟獲豁 免遵守股東批准規定。 購買事項 董事會宣佈，於二零二五年九月二十五日，本公司全資附屬公司民銀投資（香港）已於場 外交易市場購買本金總額為20,000,000美元（相當於 ...

民銀資本控股有限公司 CMBC CAPITAL HOLDINGS LIMITED （於百慕達註冊成立之有限公司） （股份代號：1141） 各位非登記股東1： 於本公司網站登載公司通訊之通知 謹此通知 閣下，民銀資本控股有限公司（「本公司」）之下述公司通訊2（「本次公司通訊」）之中、英文版本，現已 登載於本公司網站www.cmbccap.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」）網站 www.hkexnews.hk（「聯交所網站」）以供閱覽： • 2025中期報告 附註： 1. 非登記股東指將所持有之本公司股份存放於中央結算及交收系統的人士或公司。 2. 公司通訊指本公司發出或將予發出以供其任何證券的持有人或投資大眾參照或採取行動的任何文件，其中包括但不限於：－ (a) 董 事會報告、本公司的年度賬目連同核數師報告以及（如適用）財務摘要報告； (b) 中期報告及（如適用）中期摘要報告； (c) 會議通 告； (d) 上市文件； (e) 通函；及 (f) 委派代表書。 非登記股東資料（英文姓名及地址）: 申請表格 致： 民銀資本控股有限公司(股份代號：1141）(「本公司」) 經卓佳證券登記有 ...

民銀資本控股有限公司 CMBC CAPITAL HOLDINGS LIMITED （於百慕達註冊成立之有限公司） （股份代號：1141） 各位註冊股東： 於本公司網站登載公司通訊之通知 謹此通知 閣下，民銀資本控股有限公司（「本公司」）之下述公司通訊1（「本次公司通訊」）之中、英文版本， 現已登載於本公司網站www.cmbccap.com（「本公司網站」）及香港聯合交易所有限公司（「聯交所」）網站 www.hkexnews.hk（「聯交所網站」）以供閱覽： 倘 閣下對本通知有任何疑問，請致電香港股份過戶登記分處電話熱線(852) 2980 1333，辦公時間為星期一至五（公 眾假期除外）上午9時正至下午6時正，或電郵至is-ecom@vistra.com 。 • 2025中期報告 閣下現可於本公司網站「投資者關係」一欄或聯交所網站內讀取本次公司通訊。若 閣下早前曾要求收取公司通訊 的印刷本，本次公司通訊的印刷本已隨函附上。 為了支援通過電郵進行電子通訊，本公司建議 閣下向本公司香港股份過戶登記分處卓佳證券登記有限公司（「香港 股份過戶登記分處」）（地址為香港夏慤道16號遠東金融中心17樓）發出（不少於7天的） ...

Financial Performance - The group recorded revenue of approximately HKD 245.4 million, representing a year-on-year increase of about 56.7%[6] - Net profit reached approximately HKD 117.9 million, reflecting a year-on-year growth of around 48.0%[6] - The company's profit attributable to shareholders for the reporting period was approximately HKD 117.9 million, a 48.0% increase from HKD 79.7 million in the previous period[18] - Total revenue increased by approximately 56.7% to about HKD 245.4 million, up from HKD 156.7 million, primarily due to increased underwriting and sponsorship fees from bond and stock projects[19] - Basic and diluted earnings per share for the period were both HKD 10.73, compared to HKD 7.16 in the previous year, reflecting a 49.5% increase[62] - Total comprehensive income for the period was HKD 168,036,000, compared to HKD 139,314,000 in the previous year, marking a 20.6% increase[63] Revenue Sources - The increase in profit was primarily driven by significant growth in revenue from securities underwriting, sponsorship services, asset management, and wealth management-related businesses[6] - The group completed 162 bond underwriting transactions during the reporting period, a 37% increase compared to the same period last year[7] - The total underwriting scale exceeded USD 1.71 billion, marking a 44% increase year-on-year, positioning the group among the top tier in the industry[7] - Securities business revenue rose to approximately HKD 59.0 million, with a profit of HKD 28.1 million, compared to a loss of HKD 0.6 million in the previous period[20] - Fixed income direct investment revenue was approximately HKD 52.9 million, with losses decreasing to about HKD 15.8 million from HKD 22.6 million in the previous period[21] - Asset management revenue for the reporting period was approximately HKD 93.3 million, significantly up from HKD 51.5 million in the previous period[27] - Corporate finance and consulting revenue reached approximately HKD 42.9 million, compared to HKD 25.8 million in the previous period, driven by increased sponsorship and underwriting income[28] Client Base and Market Position - The client base for the group's offshore bond underwriting remains primarily composed of financial institutions and investment-grade local state-owned enterprises[7] - The offshore bond issuance by Chinese enterprises showed significant growth, with the group achieving outstanding results in the offshore debt capital market[7] - The group is focusing on high-growth potential technology innovation and healthcare companies that comply with Chapter 18A of the listing rules, actively seeking firms with strong core technology advantages and significant revenue growth potential[8] Risk Management and Compliance - The group holds licenses for regulated activities including securities trading, futures contract trading, and asset management, ensuring compliance with necessary regulations[6] - The group is implementing a risk-controlled development strategy in financing, providing customized financing solutions based on client needs, including asset-backed loans and acquisition loans[9] - The group has increased expected credit loss provisions for certain high-yield bond investments and adjusted the fair value of some equity investments based on individual circumstances[8] - The company is committed to improving risk compliance management and enhancing its overall risk management system[17] Strategic Initiatives - The group aims to leverage its international advantages and Hong Kong licensed investment banking services to promote cross-border business collaboration and meet diverse financial service needs[14] - The company aims to enhance its investment banking strategic business, focusing on sectors such as technology, media, communications, and renewable energy[15] - The company is expanding its wealth management capabilities and aims to create a one-stop trading platform for various markets, including Hong Kong and the U.S.[15] - The company plans to optimize its securities trading app to provide more efficient and secure wealth management services, incorporating user feedback mechanisms[17] - The group is actively enhancing risk management capabilities and improving corporate governance to support its strategic objectives[14] Asset Management and Investments - As of June 30, 2025, the group's investment portfolio totaled approximately HKD 2.68 billion, an increase from HKD 2.48 billion as of December 31, 2024[23] - The group's self-managed investment assets were about HKD 2.7 billion, up from HKD 2.5 billion in the previous period, with bond investments around HKD 1.9 billion[24] - Total income from the investment portfolio during the reporting period was approximately HKD 50.2 million, down from HKD 62.4 million in the previous period[24] - The group's asset management products are performing well compared to peers, with the Min Yin Rong Hui Greater China Selected Bond Fund ranking first in the three-year category for Greater China bond funds[11] Financial Position and Liabilities - The group's current assets were approximately HKD 4.89 billion as of June 30, 2025, compared to HKD 3.77 billion as of December 31, 2024[35] - The current ratio at the end of the reporting period was approximately 1.4, down from 1.6 as of December 31, 2024[35] - As of June 30, 2025, the group's debt primarily includes loans from Min Bank International amounting to approximately HKD 2,434.7 million, an increase from HKD 1,951.0 million as of December 31, 2024[36] - The capital-to-debt ratio at the end of the reporting period is approximately 61.0%, up from 58.4% as of December 31, 2024[36] - The company’s total liabilities decreased to HKD 1,819,074 thousand as of June 30, 2025, down from HKD 1,841,225 thousand at the end of 2024, indicating a reduction of 1%[65] Shareholder Actions - The board does not recommend the payment of an interim dividend for the reporting period, consistent with the previous period[48] - The company repurchased a total of 2,287,000 shares during the reporting period at a total cost of approximately HKD 0.65 million[59] - The company did not declare an interim dividend for the six months ended June 30, 2025, compared to no dividend in the previous period[89] Miscellaneous - The group has no significant contingent liabilities as of June 30, 2025, consistent with the previous year[39] - There were no major acquisitions or disposals of subsidiaries or associates during the reporting period[43] - The group has not granted any share awards under the share incentive plan since its adoption[50] - The company has not incurred any share cancellations during the six months ended June 30, 2025, following the repurchase of shares[104]

Group 1 - As of September 19, 93 stocks reached their 52-week highs, with Huake Intelligent Investment (01140), Xincheng Power (01148), and Huashang Energy (00206) leading the increase rates at 22.30%, 20.00%, and 17.65% respectively [1] - The closing prices for the top three stocks that reached new highs are Huake Intelligent Investment at 0.170, Xincheng Power at 0.300, and Huashang Energy at 0.305 [1] - Other notable stocks that reached new highs include Handa Fu Holdings (01348) with a high rate of 16.89% and Meijiehui Holdings (01389) at 13.75% [1] Group 2 - The report also lists stocks that reached their 52-week lows, with Shanga Holdings (00412) experiencing the largest decline at -34.98%, followed by Huaying Construction (01582) at -21.47% [3] - The closing price for Shanga Holdings is 3.360, while Huaying Construction closed at 0.360 [3] - Other stocks with significant declines include China Information Technology Equity (08568) at -17.74% and Tai Hing Properties (00277) at -11.90% [3]

Core Viewpoint - Minyin Capital (01141) announced that its wholly-owned subsidiary, Minyin Investment (Hong Kong), has purchased notes with a total principal amount of 15 million USD in the over-the-counter market for approximately 15.8498 million USD [1] Group 1 - The total principal amount of the notes purchased is 15 million USD [1] - The total consideration paid for the notes is approximately 15.8498 million USD [1]

Group 1 - The company, Minyin Capital (01141), announced that its wholly-owned subsidiary, Minyin Investment (Hong Kong), has purchased notes with a total principal amount of 15 million USD in the over-the-counter market [1] - The total consideration for the purchase was approximately 15.8498 million USD [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致之任何損失承擔任何責任。 上市規則的涵義 由於購買事項的最高相關適用百分比率（定義見上市規則）超出5%但低於25%，購買事 項構成本公司的須予披露的交易，須遵守上市規則第14章的匯報及公告規定，惟獲豁 免遵守股東批准規定。 – 1 – 購買事項 董事會宣佈，於二零二五年九月十六日，本公司全資附屬公司民銀投資（香港）已於場外 交易市場購買本金總額為15,000,000美元（相當於約116,881,500港元）的票據，總代價為約 15,849,781.94美元（相當於約123,503,085.85港元）。 票據的主要條款概要 民銀資本控股有限公司 CMBC CAPITAL HOLDINGS LIMITED （ 於 百 慕 達 註 冊 成 立 之 有 限 公 司 ） （股份代號：1141） 有關購買票據的須予披露的交易 購買事項 於二零二五年九月十六日，本公司全資附屬公司民銀投資（香港）已於場外交易市 場購買本金總額為15,000,00 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 民銀資本控股有限公司 呈交日期: 2025年9月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01141 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 | HKD | | 0.4 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 2,500,000,000 | HKD | | 0.4 | HKD | | 1,000,000,000 | 本月底法定/ ...

Group 1 - The company has submitted a listing application to the Hong Kong Stock Exchange, with Agricultural Bank of China International, Minyin Capital, and Fosun International Capital as joint sponsors [1] - The company focuses on developing breakthrough therapies for cancer-related diseases, while also innovating drugs for viral and age-related diseases [1] - The product portfolio includes one commercialized product, Hanai Jia, two core products (CVL009 and CVL218), and a total of 16 drug candidates in development [1] Group 2 - Hanai Jia was commercialized on June 28, 2024, generating approximately RMB 34.7 million in sales during the first half of 2024 [1] - The company has established partnerships with leading pharmaceutical companies and employs a "one drug, multiple indications" research and development model [2]